DESONIDE 21-ACETATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H34O7
Molecular Weight	458.544
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]4([H])[C@@]2([H])CCC5=CC(=O)C=C[C@]45C

InChI

InChIKey=IMVOEOHIGCNVQW-SBOGIFMKSA-N

InChI=1S/C26H34O7/c1-14(27)31-13-20(30)26-21(32-23(2,3)33-26)11-18-17-7-6-15-10-16(28)8-9-24(15,4)22(17)19(29)12-25(18,26)5/h8-10,17-19,21-22,29H,6-7,11-13H2,1-5H3/t17-,18-,19-,21+,22+,24-,25-,26+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H34O7
Molecular Weight	458.544
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848

Desonide is a topical glucocorticoid which was approved by FDA for the treatment of such conditions as eczema, psoriasis, atopic dermatitis, etc. The exact mechanism of drug action is unknown.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Atopic dermatitis 43 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician. Launch Date 1972
Eczema 46 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Seborrheic dermatitis 15 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Contact dermatitis 20 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972
Psoriasis 84 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848	Primary	Approved 8429	DESONIDE Approved Use Desonide Cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. Launch Date 1972

Doses

Dose	Population	Adverse events
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	Disc. AE: Telangiectasia... AEs leading to discontinuation/dose reduction: Telangiectasia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3
0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	Disc. AE: Cushing's syndrome, Hypothalamic pituitary adrenal axis suppression... AEs leading to discontinuation/dose reduction: Cushing's syndrome Hypothalamic pituitary adrenal axis suppression Atrophy Striae Irritation skin Acneiform eruption Skin hypopigmentation Allergic contact dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Telangiectasia	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3	unhealthy n = 425 Health Status: unhealthy Condition: Atopic dermatitis Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.3
Acneiform eruption	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Allergic contact dermatitis	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Atrophy	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Cushing's syndrome	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Hypothalamic pituitary adrenal axis suppression	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Irritation skin	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Skin hypopigmentation	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1
Striae	Disc. AE	0.05 % 2 times / day multiple, topical Recommended Dose: 0.05 %, 2 times / day Route: topical Route: multiple Dose: 0.05 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Atopic dermatitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8	yes		yes (co-administration study) Comment: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21324lbl.pdf#page=4 Page: 4,8

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:204734	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:204734
ChemicalBook	CB2783466	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2783466
MolPort	MolPort-003-987-087	https://www.molport.com/shop/molecule-link/MolPort-003-987-087
Selleck Chemicals	Desonide	http://www.selleckchem.com/products/Desonide.html
ZINC	ZINC000004212851	http://zinc15.docking.org/substances/ZINC000004212851
eMolecules	31225502	https://www.emolecules.com/cgi-bin/more?vid=31225502
eMolecules	6842825	https://www.emolecules.com/cgi-bin/more?vid=6842825

PubMed

Title	Date	PubMed
A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis.	2002	12077544
Evaluation of cross-reactivity between budesonide and desonide.	2002 Aug	12423417
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis.	2002 Aug	12121395
Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis.	2002 Jul	12072722
Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare.	2004 Sep	15324406
[Connubial contact dermatitis to an inhaled corticosteroid].	2005 Feb	15798566
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences.	2005 Mar-Apr	15767771
Rapid resolution of a common problem.	2005 May	15866247
A novel hydrogel vehicle formulated for the treatment of atopic dermatitis.	2007 Jul	17763596
Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis.	2007 Jun	17713152
Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis.	2007 May-Jun	17542883
Tega-dermabrasion.	2007 Sep	17721261
Desonide gel.	2007 Sep-Oct	17786103
Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome.	2008 Aug	18258739
Desonide: a review of formulations, efficacy and safety.	2008 Jul	18549345
Fixed drug eruption induced by atenolol.	2009 Apr 24	21437137
Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.	2009 Jul 2	19829884
Manifestations of cutaneous sarcoidosis: a case report of an African American woman.	2009 Jun	19585935
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009 Oct 2	19798416
Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories.	2010 Apr	20155493

Patents

Sample Use Guides

In Vivo Use Guide

Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.

Route of Administration: Topical

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:15:29 GMT 2023` Edited by `admin` on `Sat Dec 16 05:15:29 GMT 2023`
Record UNII	45JZL0UFSD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DESONIDE 21-ACETATE

Common Name

English

ACETYLDESONIDE [USP IMPURITY]

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 11.BETA.,16.ALPHA.,17,21-TETRAHYDROXY-, CYCLIC 16,17-ACETAL WITH ACETONE, 21-ACETATE

Systematic Name

English

11B,21-DIHYDROXY-16A,17A-ISOPROPYLIDENEDIOXY-1,4-PREGNADIENE-3,20-DIONE-21-ACETATE

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (11.BETA.,16.ALPHA.)-

Common Name

English

Code System Code Type Description

CAS

25092-25-5

Created by admin on Sat Dec 16 05:15:29 GMT 2023 , Edited by admin on Sat Dec 16 05:15:29 GMT 2023

PRIMARY

PUBCHEM

15391900

Created by admin on Sat Dec 16 05:15:29 GMT 2023 , Edited by admin on Sat Dec 16 05:15:29 GMT 2023

PRIMARY

FDA UNII

45JZL0UFSD

Created by admin on Sat Dec 16 05:15:29 GMT 2023 , Edited by admin on Sat Dec 16 05:15:29 GMT 2023

PRIMARY

RS_ITEM_NUM

1A01420

Created by admin on Sat Dec 16 05:15:29 GMT 2023 , Edited by admin on Sat Dec 16 05:15:29 GMT 2023

PRIMARY

Related Record Type Details


					J280872D1O

DESONIDE

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

Related Record Type Details


					J280872D1O

DESONIDE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848

Approval Year

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Doses

AEs

Overview

OverviewOther

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db13f47-aaab-4054-8b0d-0e23d44dc848